Impact of dose rate on clinical course in uveal melanoma after brachytherapy with ruthenium-106

Strahlentherapie und Onkologie

Volumn 183, Issue 10, 2007, Pages 571-575

  Mossböck, Georg ^a   Rauscher, Thomas ^a   Winkler, Peter ^a   Kapp, Karin S ^a   Langmann, Gerald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Dose rate; Ruthenium 106; Uveal melanoma

Indexed keywords

RUTHENIUM 106;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SCLERA; STATISTICAL SIGNIFICANCE; TUMOR VOLUME; UNIVARIATE ANALYSIS; UVEA MELANOMA; VISUAL ACUITY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RETINAL DISEASES; RETROSPECTIVE STUDIES; RISK FACTORS; RUTHENIUM RADIOISOTOPES; TIME FACTORS; UVEAL NEOPLASMS; VISUAL ACUITY;

EID: 34748814932     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1734-x     Document Type: Article

References (27)

1. Augsburger JJ, Gonder JR, Amsel J, et al. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology 1984;91:1709-15.
2. Beitler JJ, McCormick B, Ellsworth RM, et al. Ocular melanoma: total dose and dose rate effects with Co-60 plaque therapy. Radiology 1990;176:275-8.
3. Bornfeld N. Proton treatment of uveal melanomas. Strahlenther Onkol 2007;183:1-2.
4. Dieckmann K, Georg D, Zehetmayer M, et al. LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. Radiother Oncol 2003;67:199-206.
5. Diener-West M, Earle JD, Fine SL, et al., Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001;119:969-82.
6. Folberg R, Rummelt V, Parys-Van Ginderdeuren, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100:1389-98.
7. Gündüz K, Shields CL, Shields JA, et al. Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999;117:609-14.
8. Hall EJ. Weiss lecture. The dose-rate factor in radiation biology. Int J Radiat Biol 1991;59:595-610.
9. Hocht S, Stark R, Seiler F, et al. Proton or stereotactic photon irradiation for posterior uveal melanoma? A planning intercomparison. Strahlenther Onkol 2005;181:783-8.
10. Jones R, Gore E, Mieler W, et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002;52:989-95.
11. Kaiserman I, Anteby I, Chowers I, et al. Changes in ultrasound findings in posterior uveal melanoma after ruthenium 106 brachytherapy. Ophthalmology 2002;109:1137-41.
12. 106Ru plaques. Ger J Ophthalmol 1994;3:22-5.
13. Kleineidam M, Guthoff R, Schiller F, et al. Radiotherapy of the R1H-tumor: dose-rate effect on tumor response in brachytherapy with 106-ruthenium eye applicators. Int J Radiat Oncol Biol Phys 1993 15;25:277-81.
14. Langmann G, Pendl G, Klaus-Mullner, et al. Gamma knife radiosurgery for uveal melanomas: an 8-year experience. J Neurosurg 2000;93:Suppl 3:184-8.
15. Langmann G, Pendl G, Mullner K, et al. High- compared with low-dose radiosurgery for uveal melanomas. J Neurosurg 2002;97:Suppl 5:640-3.
16. Lommatzsch P, Vollmar R. [A new way in the conservative therapy of intraocular tumors by means of beta-irradiation (Ruthenium 106) with preservation of vision.] Klin Monatsbl Augenheilkd 1966;148:682-99.
17. 106Rh).] Klin Monatsbl Augenheilkd 1986;189:133-40.
18. Marnitz S, Cordini D, Bendl R, et al. Proton therapy of uveal melanomas: intercomparison of MRI-based and conventional treatment planning. Strahlenther Onkol 2006;182:395-9.
19. McLean IW, Foster WD, Zimmermann LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982;13:123-32.
20. Moore RF. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol 1930;14:145-6.
21. 125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer 1996;77:2356-62.
22. Rotman M, Long RS, Packer S, et al. Radiation therapy of choroidal melanoma. Trans Ophthalmol Soc U K 1977;97:431-5.
23. Schueller P, Dogan A, Panke JE, et al. Does the imaging method have an influence on the measured tumor height in ruthenium plaque therapy of uveal melanoma? Strahlenther Onkol 2005;181:320-5.
24. Stallard HB. Radiotherapy for malignant melanoma of the choroid. Br J Ophthalmol 1966;50:147-55.
25. Sterzing F, Munter MW, Schafer M, et al. Radiobiological investigation of dose-rate effects in intensity-modulated radiation therapy. Strahlenther Onkol 2005;181:42-8.
26. Vogler H, Beck-Bornholdt HP. Radiotherapy of the rhabdomyosarcoma R1H of the rat: kinetics of cellular inactivation by fractionated irradiation. Int J Radiat Oncol Biol Phys 1988;14:317-25.
27. 125I irradiation on normal rabbit eyes and experimental choroidal melanoma. Exp Eye Res 1993;57:577-85.